Rewriting a gene without breaking DNA: US launches trials of new gene therapy
The therapy is being tested on people with Wilson's disease: a hereditary condition in which a mutation in the ATP7B gene causes copper to accumulate in the body, damaging the liver and brain.

Currently, patients have to take medication for life.
Prime editing, described in 2019, allows for precise modification of a DNA segment without breaking both of its strands. PM577a targets the H1069Q variant, which accounts for up to half of pathogenic alleles in Europe and North America. In experiments on mice, the gene was corrected in over 80% of liver cells.
The study will include 42 people, and the first results are expected in 2027. It is not yet known whether the drug has worked in humans, so this represents an important technological milestone rather than a cure.





